Peretz N M, Goldberg H, Kuten A, Meller I, Krivoi E, Lorber A, Bentur L, Lightman A, Gorenberg V, Ben Arush-Weyl M
Pediatric Hematology-Oncology Dept., Oncology Center, Pediatric Cardiology Unit, Rambam Medical Center and Technion-Israel Institute of Technology, Haifa.
Harefuah. 2001 Feb;140(2):95-100, 192, 191.
110 children with malignant diseases (leukemia excepted) who survived 5-20 years (median 9) post-therapy were followed (1996-1998). Median age during follow-up was 15 years (range 5-23). The most common malignancies were brain tumors, lymphoma, retinoblastoma and Wilm's tumor. The 174 late side-effects included endocrine disorders (19%), cognitive impairment (14%), orthopedic dysfunction (12%), alopecia (12%), dental damage (11%), psychological (8%) and neurological (8%) disturbances, and azoospermia or amenorrhea (5%). There was no cardiac or renal damage and no second malignancy. 29% of side-effects were severe. There was significant reduction in quality of life in 54 (49%), in 27 of whom it was severe enough to require psychological intervention. Treatment of brain tumor caused 98 late side-effects in 28 patients (sequelae-to-patient ratio [SPR] 3.3). Most cognitive, endocrine and neurological disorders, and most cases of alopecia, dental and psychological difficulties were in these patients. There were frequent late complications in those treated for retinoblastoma (SPR 1.8), and bone or soft tissue sarcomas (SPR 0.8). Those treated for Wilm's tumor had few side-effects (SPR 0.4). Late side effects were most frequent after radiation, reaching as high as SPR 2.4. It averaged only 0.5 in those treated with chemotherapy alone or in combination with surgery. Reduction of late side-effects in these patients requires using less toxic modalities, as long as cure rate is not compromised. When considering secondary strategies, screening for early detection of late complications would enable immediate solutions, such as hormonal replacement or providing compensating skills for post-treatment disability.
对110名患有恶性疾病(不包括白血病)且在治疗后存活5至20年(中位数为9年)的儿童进行了随访(1996 - 1998年)。随访期间的中位年龄为15岁(范围为5至23岁)。最常见的恶性肿瘤是脑肿瘤、淋巴瘤、视网膜母细胞瘤和肾母细胞瘤。174例晚期副作用包括内分泌紊乱(19%)、认知障碍(14%)、骨科功能障碍(12%)、脱发(12%)、牙齿损伤(11%)、心理(8%)和神经(8%)紊乱,以及无精子症或闭经(5%)。没有心脏或肾脏损伤,也没有二次恶性肿瘤。29%的副作用较为严重。54名患者(49%)的生活质量有显著下降,其中27名患者的生活质量下降严重到需要心理干预。脑肿瘤治疗导致28名患者出现98例晚期副作用(后遗症与患者比例[SPR]为3.3)。大多数认知、内分泌和神经紊乱,以及大多数脱发、牙齿和心理问题都出现在这些患者中。视网膜母细胞瘤患者(SPR为1.8)以及骨肉瘤或软组织肉瘤患者(SPR为0.8)经常出现晚期并发症。肾母细胞瘤患者的副作用较少(SPR为0.4)。放疗后晚期副作用最为常见,高达SPR 2.4。单独使用化疗或化疗联合手术治疗的患者平均仅为0.5。在不影响治愈率的前提下,减少这些患者的晚期副作用需要使用毒性较小的治疗方式。在考虑二级策略时,对晚期并发症进行早期检测的筛查将能够立即采取解决方案,如激素替代或为治疗后残疾提供补偿技能。